Translating a biostimulatory implant for the long-term treatment of glottic insufficiency

RFA-DC-22-001：翻译生物刺激植入物用于声门炎的长期治疗 不足 摘要 声门功能不全(GI)是一种喉部疾病，可损害沟通和吞咽 由于声带麻痹、喉咙老化症、创伤、手术或放射而导致的功能障碍。最常见的 胃肠道感染的治疗是用临时的纳米多孔生物材料增强声带，以帮助 声门关闭。然而，目前可用的材料很难恢复生物力学性能 天然声带，可与密集的组织细胞反应有关，但仅持续三个月 到18个月。此外，声带是一种复杂的板层组织，能够发出声音 由于细胞外基质和细胞成分的特殊机械特性。然而， 声带扩大术的结构、细胞和内在机械效应尚未得到证实。 完全具有特征的，特别是在原位实现动态平衡之后。需要一口井 特制和有目的的可注射植入物，可恢复永久性喉部 功能不会产生炎症或影响声带的柔韧性。为了满足这一需求， 我们开发了一种新型的微孔退火颗粒(MAP)支架，即 生物力学与声带匹配，能够促进组织整合，并提供 持久的组织块。该建议旨在(1)开发与地图相关的从头测定法 组织形成，(2)表征体内给药的临床可行性，(3)确定 毒理学概况和(4)启动MAP水凝胶声带的首个人类临床试验 增强功能。

RFA-DC-22-001: Translating a biostimulatory implant for the long-term treatment of glottic insufficiency Abstract Glottic insufficiency (GI) is a laryngeal disorder that can impair communication and swallowing function due to vocal fold paralysis, presbylarynges, trauma, surgery, or radiation. The most common treatment for GI is vocal fold augmentation with temporary nanoporous biomaterials that assist with glottic closure. However, currently available materials poorly restore the biomechanical properties of the native vocal fold and can be associated with dense histiocytic responses, while only lasting three to eighteen months. In addition, vocal folds are a complex laminar tissue capable of producing voice due to specific mechanical properties of the extracellular matrix and cellular components. However, the structural, cellular, and intrinsic mechanical effects of vocal fold augmentation have not yet been fully characterized, particularly after achieving homeostasis in situ. There is a need for a well characterized and purposefully-designed injectable implant that can restore permanent laryngeal function without producing inflammation or compromising vocal fold pliability. To address this need, we developed a novel iteration of microporous annealed particle (MAP) scaffold that is biomechanically matched to the vocal fold, capable of promoting tissue integration, and providing persistent tissue bulk. This proposal aims to (1) develop assays of MAP-associated de novo tissue formation, (2) characterize the clinical feasibility of in vivo delivery, (3) determine the toxicology profile and (4) initiate a first-in-human clinical trial of MAP hydrogel vocal fold augmentation.